CD8A and familial pancreatic carcinoma: In this study, we reported for the first time the clinical trial, making use of the integrated approach with iNKT and PD-1+CD8+ T cells to treat patients with pancreatic cancers that had failed first-line chemotherapy, which was included in NCT03093688, with the primary endpoint of safety, and secondary endpoints of response rate and survival.